Phio Pharmaceuticals Corp (PHIO) Stock Price, Quote & News

Company Profile

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma a...

Industry: Biotechnology

Sector: Healthcare

Phone: 508 767 3861

Website: phiopharma.com

Address:

11 Apex Drive, Suite 300A PMB 2006, Marlborough, United States

Decodedthemkt Jul. 28 at 12:12 AM

$PHIO this week the market will understood this news super bullish for this week

0 · Reply

ChartChartist Jul. 27 at 7:27 PM

$PHIO flip $LHAI like the effort A+ $ATNF 3.5 breaks and damn $YAAS still trading dont lose sight $ olb a top watching to get some trades in Monday early from momo

0 · Reply

goldenjayca Jul. 27 at 9:46 AM

$PHIO https://www.ainvest.com/news/phio-pharmaceuticals-ph-762-trial-game-changer-surgical-skin-cancer-treatment-2507/

0 · Reply

BlackBerril Jul. 26 at 1:48 PM

$PHIO Blocking all spammers. PHIO is a solid buy & hold. If you’re just playing for pennies pay to subscribe to one of these pathetic losers posting on the weekend about all their “gains” on multiple tickers.

0 · Reply

XkaliburTrading Jul. 26 at 12:41 AM

Hello and good Friday everyone followers and Team! The market is coming to a close and I hope you all did amazing today! Hope you all enjoy the rest of the day and the time with your family friends or loved ones this weekend! 🫡 (Part 2) End of day spotted at recap: $MCVT at 2.23 hod at 13.00 🔥🔥🔥🔥🚀 $PHIO at 2.58 hod at 4.14 👌 $OCTO at 2.01 hod at 2.40 🤷‍♂️

0 · Reply

IndicatorGator Jul. 25 at 11:38 PM

Results from 25 July 25 Watchlist (WL) and Alerts -See Pinned Post on Profile to Join Us for Alerts, Watchlist, Education, Swing Trades and PROFITS! -FOLLOW and SUBSCRIBE. MCVT: 3.20 to $13 (306%) Alert SMX: 1.18 to 2.42 (105%) WL HCTI: .045 to .09 (100%) WL WLGS: .086 to .12 (39%) WL LIDR: $4 to 5.35 (33%) Alert $PHIO: 3.10 to 4.15 (33%) Alert $LHAI: 11.50 to 14.70 (27%) Alert $OCTO: 1.90 to 2.39 (25%) WL

0 · Reply

Almamm Jul. 25 at 10:44 PM

$PHIO my position 3.21 what do you recommend for me guys I’m really got lost in this market .. I lost my money in this market !!! There’s no protection for investors from 40k remains only 4k

4 · Reply

BrocM Jul. 25 at 10:43 PM

$PHIO notice how they only reported on 4 out of 5 patients of cohort 4. I wonder why theyre waiting for the 5th patients reaults... it couldnt be that they're waiting for monday morning to announce the 5th patients results of 100% tumor clearance and negate the price action of the warrant news right? 😏 know what you hold people. $MCVT

3 · Reply

WildernessRefuge Jul. 25 at 9:57 PM

$PHIO The existing Series G warrants cashed, at least in part. The price was determined at the beginning of the year. There is a 50% dilution overhanging the stock price from Series F through I (the existing warrants issued at realistic prices). When modeling the stock, we use outstanding shares as 9.5 million- everyone else should too.

0 · Reply

BreakoutBullz Jul. 25 at 9:15 PM

Have a great weekend, everyone!💰 Link in bio! See you on Monday at 4 AM ET! 🕓 Some of our plays from today! 🔥💰🎯 $MCVT $LIDR $OCTO $PHIO $HTOO

0 · Reply

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025, 12:36 PM EDT - 2 days ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025, 7:45 AM EDT - 2 days ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jun 25, 2025, 7:45 AM EDT - 4 weeks ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 24, 2025, 7:45 AM EDT - 4 weeks ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 6, 2025, 7:45 AM EDT - 7 weeks ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

May 19, 2025, 7:45 AM EDT - 2 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 15, 2025, 4:15 PM EDT - 2 months ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 7:45 AM EDT - 2 months ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Apr 9, 2025, 7:45 AM EDT - 3 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 3, 2025, 7:45 AM EDT - 4 months ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Mar 31, 2025, 4:00 PM EDT - 4 months ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 10, 2025, 7:45 AM EDT - 4 months ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 5, 2025, 7:45 AM EST - 5 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Feb 20, 2025, 7:45 AM EST - 5 months ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Jan 22, 2025, 7:00 AM EST - 6 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jan 21, 2025, 4:15 PM EST - 6 months ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 16, 2025, 1:00 PM EST - 6 months ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025, 7:00 AM EST - 6 months ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025, 7:00 AM EST - 6 months ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 13, 2025, 12:45 PM EST - 6 months ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Jan 13, 2025, 7:45 AM EST - 6 months ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 2, 2025, 7:45 AM EST - 7 months ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Dec 23, 2024, 1:15 PM EST - 7 months ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 7 months ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 7:45 AM EST - 7 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 12, 2024, 9:21 AM EST - 8 months ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 10, 2024, 7:45 AM EST - 8 months ago

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Nov 19, 2024, 7:45 AM EST - 8 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 14, 2024, 5:47 PM EST - 9 months ago

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 10:00 AM EST - 9 months ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 18, 2024, 1:30 PM EDT - 10 months ago

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Oct 18, 2024, 8:00 AM EDT - 10 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Oct 16, 2024, 8:00 AM EDT - 10 months ago

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Oct 7, 2024, 8:00 AM EDT - 10 months ago

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

Sep 25, 2024, 8:00 AM EDT - 10 months ago

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Sep 16, 2024, 8:00 AM EDT - 11 months ago

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Sep 9, 2024, 7:00 AM EDT - 11 months ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 5:00 PM EDT - 1 year ago

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces New Chief Financial Officer

Jul 12, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Jul 8, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

Jul 5, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

Jul 2, 2024, 11:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Reverse Stock Split

Jun 18, 2024, 7:30 AM EDT - 1 year ago

Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging

May 28, 2024, 7:30 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762

May 23, 2024, 5:00 PM EDT - 1 year ago

Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

May 17, 2024, 9:00 AM EDT - 1 year ago

Phio Pharmaceuticals Secures New Investor

May 15, 2024, 1:00 PM EDT - 1 year ago

Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

Decodedthemkt Jul. 28 at 12:12 AM

$PHIO this week the market will understood this news super bullish for this week

0 · Reply

ChartChartist Jul. 27 at 7:27 PM

$PHIO flip $LHAI like the effort A+ $ATNF 3.5 breaks and damn $YAAS still trading dont lose sight $ olb a top watching to get some trades in Monday early from momo

0 · Reply

goldenjayca Jul. 27 at 9:46 AM

$PHIO https://www.ainvest.com/news/phio-pharmaceuticals-ph-762-trial-game-changer-surgical-skin-cancer-treatment-2507/

0 · Reply

BlackBerril Jul. 26 at 1:48 PM

0 · Reply

XkaliburTrading Jul. 26 at 12:41 AM

0 · Reply

IndicatorGator Jul. 25 at 11:38 PM

0 · Reply

Almamm Jul. 25 at 10:44 PM

$PHIO my position 3.21 what do you recommend for me guys I’m really got lost in this market .. I lost my money in this market !!! There’s no protection for investors from 40k remains only 4k

4 · Reply

BrocM Jul. 25 at 10:43 PM

3 · Reply

WildernessRefuge Jul. 25 at 9:57 PM

0 · Reply

BreakoutBullz Jul. 25 at 9:15 PM

Have a great weekend, everyone!💰 Link in bio! See you on Monday at 4 AM ET! 🕓 Some of our plays from today! 🔥💰🎯 $MCVT $LIDR $OCTO $PHIO $HTOO

0 · Reply

DosGatos Jul. 25 at 9:02 PM

$PHIO Grab a seat lol!

1 · Reply

BrocM Jul. 25 at 8:41 PM

$PHIO let my guy Robert Bitterman cook, im chillin, waiting for my PT. It'll hit, no question, only a matter of time.

0 · Reply

mikailoral Jul. 25 at 8:27 PM

$PHIO This much good news should have been doubled by now.

0 · Reply

stoxrgood Jul. 25 at 8:21 PM

$PHIO be like $2.75...$3.00...$3.50...$4

0 · Reply

Sir_Wolf_Of_Wall_Street Jul. 25 at 8:08 PM

$PHIO Let's fucking go!!!

3 · Reply

stoxrgood Jul. 25 at 7:55 PM

$PHIO ready for the after hours rebound!!

0 · Reply

BrocM Jul. 25 at 7:48 PM

$PHIO guys... drug development isnt free lol. If you want capable people to work for you then you need to pay them, obviously. The important thing is they secured a manufacturer agreement which means they're confident in bringing intasyl to market, and the trials which were only meant to determine safety also show unprecedented efficacy. Im not flipping for pennies, instead holding for gold, as i have been from the start, because i see the insanely huge potential. Be smart.

1 · Reply

BlackBerril Jul. 25 at 7:47 PM

$PHIO Totally disproportionate reaction. We should bounce well above $3 if the market was even remotely rational. Cancer treatment results alone should send this flying. Management does have a knack for bad timing, but no reason not to be bullish here.

0 · Reply

Scratcher Jul. 25 at 7:47 PM

$PHIO Wall Street just chewed me up and spit me the F out !!

1 · Reply

Mikey6028 Jul. 25 at 7:45 PM

$PHIO WELL, THAT WAS ALOT OF BS... GUESS I WILL BUY THE DIP IN AFTER HOURS.. HOPEFULLY IT CONTINUES BULLISH THE NEXT FEW DAYS.. IF THE CHART CONTINUES ON THE ROAD ITS BEEN ON, WE SHOULD BE OK..

0 · Reply

mikailoral Jul. 25 at 7:43 PM

$PHIO

0 · Reply

uptrend2025 Jul. 25 at 7:43 PM

$PHIO 👇🤑Sometimes it’s better a smaller but secure profit! Anyhow, warrants are not that bad. Still bullish long term.

1 · Reply

Market Cap	13.15M
Revenue (ttm)	0.00
Net Income (ttm)	-7.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	49,543,000
Avg Vol	1,361,904
Day's Range	N/A - N/A
Shares Out	4.80M
Stochastic %K	36%
Beta	0.91
Analysts	Strong Sell
Price Target	$14.00